publikationen

publikationen
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer:
A Randomized Multicenter Phase II Trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer
Study Group
Jalid Sehouli, Dirk Stengel, Philipp Harter, Christian Kurzeder, Antje Belau, Thomas Bogenrieder, Susanne Markmann, Sven Mahner, Lothar Mueller, Ralf Lorenz, Andreas Nugent, Jochen Wilke, Andreas Kuznik, Gabriele Doering, Arthur Wischnik, Harald Sommer, Hans-Gerd Meerpohl,
Willibald Schroeder, Werner Lichtenegger, and Guelten Oskay-Oezcelik
J Clin Oncol, January 10, 2011 vol. 29:242-248.
 
Trastuzumab treatment of early breast cancer:
Long-term results from a prospective observation study, including a large cohort of elderly patients 
P Dall, G Lenzen, T Göhler, G Feisel-Schwickeradi, T Koch, V Heilmann, C Schindler, J Wilke, H Tesch, J Selbach, J Eggert, and A Hinke
Cancer Res 2013;73(24 Suppl): Abstract nr P2-15-02.
 
Trastuzumab in the treatment of elderly patients with early breast cancer:
Results from a observational study in Germany 
P Dall, G Lenzen, T Göhler, G Feisel-Schwickeradi, T Koch, V Heilmann, C Schindler, J Wilke, H Tesch, J Selbach, J Eggert, and A Hinke
J Geriatr Oncol (2015) Nov;6(6):462-9.
 
Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer:
a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Sehouli J. Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G. 
J Clin Oncol. 2011 Jan 10;29(2):242-8.